Hepatitis B virus genotypes and subgenotypes and the natural history and epidemiology of hepatitis B

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
DUQUE, Ulisses Horst
CARVALHO, Jose Americo
PERINI, Waltesia
QUEIROZ, Marcello Moro
SEGAL, Ingrid Marques
Citação
ANNALS OF HEPATOLOGY, v.27, suppl.1, Special Issue, article ID 100574, 7p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction and Objectives: Espirito Santo state is considered a region with a higher frequency of hepatitis B virus infection. This study characterized demographic, epidemiological, laboratory, virological and clinical aspects of 587 chronic HBV carriers followed up at the University of Espirito Santo Hospital. Materials and Methods: Demographic, epidemiological, laboratory and clinical data were extracted from medical records during the entire follow-up period. Classification of the evolutionary phases of chronic hepatitis B was defined as immunotolerant; inactive carrier; chronic active hepatitis HBeAg (+) and HBeAg (-). Characterization of HBV genotypes/subgenotypes was performed by sequencing of overlapping surface antigens and HBV DNA polymerase genes. Phylogenetic relationships were determined using BEAST 1.8.3 software. Results: and Conclusions: Genotypes found were A (132/65.3%) [A1 = 129 (63.9%) and A2 = 3 (1.5%)], D (66/32.7%) [D3 = 56 (27.7%), D4 = 8 (4.0%) and D2 = 2 (1.0%)] and F (4/2.0%) - all F2a. Subgenotypes A1 or D3 were not associated with age, sex, HIV/HCV co-infection, viral load, antiviral usage, HBeAg status or clinical stages of chronic hepatitis B. Mother -to-child-transmission (MTCT) was associated with the subgenotype A1 and intrafamilial transmission with subgenotype D3. Subgenotype A1 was more frequent than D3 among individuals born outside ES compared to those born in ES. Conclusions: The most predominant clinical phases were HBeAg (-), inactive carrier and chronic active hepatitis HBeAg (-). Subgenotypes A1 and D3 were most frequent and were associated were MTCT and intrafamilial transmission of HBV, respectively. (C) 2021 Fundacion Clinica Medica Sur, A.C.
Palavras-chave
Hepatitis B, Natural history of disease, Brazil, Genotype
Referências
  1. Agarwal A K, 2015, Med J Armed Forces India, V71, P225, DOI 10.1016/j.mjafi.2015.04.003
  2. Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
  3. Chen P, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.7604
  4. Cunha-Silva M, 2017, BRAZ J INFECT DIS, V21, P441, DOI 10.1016/j.bjid.2017.03.019
  5. de Paoli J, 2018, BRAZ J INFECT DIS, V22, P294, DOI 10.1016/j.bjid.2018.06.006
  6. ESPIRITO SANTO (ESTADO). SECRETARIA DA SAUDE, 2011, PLAN DIR REG SAUD PD
  7. Fattovich G, 2008, J HEPATOL, V48, P335, DOI 10.1016/j.jhep.2007.11.011
  8. Ferraz ML, 2020, BRAZ J INFECT DIS, V24, P434, DOI 10.1016/j.bjid.2020.07.012
  9. Chacha SGF, 2017, BRAZ J INFECT DIS, V21, P424, DOI 10.1016/j.bjid.2017.01.011
  10. Galizzi J, 2010, HEPATOL INT, V4, P511, DOI 10.1007/s12072-010-9178-2
  11. GAUVREAU K, 1994, NUTRITION, V10, P184
  12. GAUVREAU K, 1993, NUTRITION, V9, P386
  13. Gomes MMS, 2005, THESIS PROGRAMA POS
  14. Gomes-Gouvea MS, 2015, ANTIVIR THER, V20, P387, DOI 10.3851/IMP2938
  15. Goncalves PL, 2014, REV SOC BRAS MED TRO, V47, P559, DOI 10.1590/0037-8682-0145-2014
  16. Gusatti CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135816
  17. Hall T., 1999, NUCL ACIDS S SER, V41, P95
  18. Kramvis A, 2016, REV MED VIROL, V26, P285, DOI 10.1002/rmv.1885
  19. Lago BV, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090860
  20. Lobato C, 2006, J GASTROEN HEPATOL, V21, P863, DOI 10.1111/j.1440-1746.2006.04298.x
  21. McMahon BJ, 2014, CLIN GASTROENTEROL H, V12, P701, DOI 10.1016/j.cgh.2013.09.005
  22. Pinho JRR, 2017, CURR TREAT OPT INFEC, V9, P18
  23. Pinho-Nascimento CA, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00120-18
  24. Ragheb M, 2012, J MED VIROL, V84, P587, DOI 10.1002/jmv.23234
  25. Saletto N., 2000, DIMENSOES, V11, P99
  26. Sali Shahnaz, 2019, Avicenna Journal of Medical Biotechnology, V11, P221
  27. Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
  28. Tajiri H, 2007, J MED VIROL, V79, P922, DOI 10.1002/jmv.20916
  29. Zampino R, 2002, J HEPATOL, V36, P248, DOI 10.1016/S0168-8278(01)00253-7
  30. Zampino R, 2015, WORLD J GASTROENTERO, V21, P11941, DOI 10.3748/wjg.v21.i42.11941